Valuation: Exagen Inc.

Market Cap 109M 95.14M 88.55M 81.3M 154M 10.45B 156M 1.04B 410M 5.2B 411M 402M 17.44B P/E 2026 *
-6.57x
P/E 2027 * -8.88x
Enterprise Value 109M 95.14M 88.55M 81.3M 154M 10.45B 156M 1.04B 410M 5.2B 411M 402M 17.44B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.38x
Free-Float
57.84%
Yield 2026 *
-
Yield 2027 * -
1 day-3.00%
1 week-3.21%
1 month-3.82%
3 months+48.04%
6 months+23.10%
Current year-25.49%
1 week 4.09
Extreme 4.09
4.89
1 month 4.05
Extreme 4.05
5.11
Current year 2.59
Extreme 2.59
6.75
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.9
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 17/10/2022
Director of Finance/CFO 57 01/09/2024
Chief Tech/Sci/R&D Officer - 23/06/2025
Director TitleAgeSince
Chairman 72 19/01/2023
Director/Board Member 63 30/07/2019
Director/Board Member 56 17/06/2021
Date Insider Type Main position Quantity % Market Cap.
24/02/26 Sell

Chief Executive Officer

11,430 0.0504%
24/02/26 Sell

Chief Financial Officer

1,584 0.0070%
16/10/25 Sell

Chief Executive Officer

31,787 0.1445%
Change 5-day change 1-year change 3-year change Capi.($)
-3.00%-3.21%-47.51%+81.20% 109M
-0.70%+2.20%+98.96%+490.30% 38.35B
-2.01%+4.19%+18.24%+44.75% 25.01B
-2.84%+3.02%-20.04%-37.76% 7.58B
+1.74%+3.59%+16.62%+90.05% 5.02B
+1.41%+8.30%+19.93%+62.23% 3.33B
-3.72%+10.08%+196.32%-12.83% 1.96B
-5.58%+10.17%-35.92%+754.46% 1.93B
+2.28%+6.89%-11.70%-60.62% 1.9B
+11.30%+5.41%+20.37%+8.41% 1.83B
Average -0.11%+4.80%+25.53%+142.02% 8.7B
Weighted average by Cap. -0.90%+3.59%+52.56%+248.59%

Financials

2026 *2027 *
Net sales 71.67M 62.3M 57.99M 53.24M 101M 6.84B 102M 684M 268M 3.41B 269M 263M 11.42B 79.39M 69.01M 64.23M 58.97M 111M 7.58B 113M 757M 297M 3.77B 298M 292M 12.65B
Net income -16.93M -14.72M -13.7M -12.58M -23.76M -1.62B -24.12M -162M -63.38M -805M -63.59M -62.2M -2.7B -13M -11.3M -10.52M -9.66M -18.24M -1.24B -18.52M -124M -48.66M -618M -48.82M -47.75M -2.07B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
31/07/26 $4.530 -3.00% 106,474
30/07/26 $4.670 +7.36% 98,936
29/07/26 $4.350 -2.25% 188,561
28/07/26 $4.450 +1.14% 270,255
27/07/26 $4.400 -5.98% 201,761
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.530USD
Average target price
8.571USD
Spread / Average Target
+89.21%

Quarterly revenue - Rate of surprise